Cited by 259Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology ResearchAutism Spectrum Disorder Research

Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome

Open access
Krueger, Dilja D., Bear, Mark F.·2011·Annual Review of Medicine

Abstract

Fragile X syndrome (FXS) is the most common inherited form of mental retardation and a leading known cause of autism. It is caused by loss of expression of the fragile X mental retardation protein (FMRP), an RNA-binding protein that negatively regulates protein synthesis. In neurons, multiple lines of evidence suggest that protein synthesis at synapses is triggered by activation of group 1 metabotropic glutamate receptors (Gp1 mGluRs) and that many functional consequences of activating these receptors are altered in the absence of FMRP. These observations have led to the theory that exaggerated protein synthesis downstream of Gp1 mGluRs is a core pathogenic mechanism in FXS. This excess can be corrected by reducing signaling by Gp1 mGluRs, and numerous studies have shown that inhibition of mGluR5, in particular, can ameliorate multiple mutant phenotypes in animal models of FXS. Clinical trials based on this therapeutic strategy are currently under way. FXS is therefore poised to be the first neurobehavioral disorder in which corrective treatments have been developed from the bottom up: from gene identification to pathophysiology in animals to novel therapeutics in humans. The insights gained from FXS and other autism-related single-gene disorders may also assist in identifying molecular mechanisms and potential treatment approaches for idiopathic autism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev-med-061109-134644

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Krueger, D. D., & Bear, M. F.
Affiliations
  • The Picower Institute for Learning and Memory, Howard Hughes Medical Institute, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139;
  • Howard Hughes Medical Institute (US)
Venue
Annual Review of Medicine
Published
2011-02-18
Volume
62
Issue
1
Pages
411-429
ISSN
  • 0066-4219 (ISSN-L)
  • 1545-326X
OpenAlex
W2162507760
Cited by
259
References
101
Citations by year
2026: 3 · 2025: 5 · 2024: 5 · 2022: 8 · 2021: 11 · 2020: 13 · 2019: 3 · 2018: 5 · 2017: 14 · 2016: 12 · 2015: 27 · 2014: 38 · 2013: 38 · 2012: 61
FWCI
3.89
Type
journal article
Language
en
Open access
Locations
  • Annual Review of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Foundation for the National Institutes of Health
  • Howard Hughes Medical Institute
  • FRAXA Research Foundation
  • National Institute of Child Health and Human Development
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD046943)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
Keywords
fragile X syndrome, FMRP, group I metabotropic glutamate receptors, mGluR5, synaptic protein synthesis, autism spectrum disorder, intellectual disability, mGluR5 antagonist, autism treatment, idiopathic autism
MeSH terms
Animals, Autistic Disorder, Clinical Trials as Topic, Fragile X Syndrome, Humans, Neurofibromatosis 1, Neuronal Plasticity, Tuberous Sclerosis, Rett Syndrome, Receptors, Metabotropic Glutamate, PTEN Phosphohydrolase, Mice, Fragile X Mental Retardation Protein, Fragile X Messenger Ribonucleoprotein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review